Access cutting-edge giant cell arteritis treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access giant cell arteritis specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related giant cell arteritis treatment provided free
This randomized, double-blind, placebo-controlled trial will seek to determine the efficacy of abatacept in GCA. To examine this objective, 62 eligible patients who have newly diagnosed or relapsing GCA within 8 weeks prior to screening will be randomized at a 1:1 ratio to receive subcutaneous abatacept 125mg/week or placebo. Patients who achieve remission will remain on their blinded assignment for 12 months at which time abatacept/placebo will be stopped. Patients who do not achieve remission
Sponsor: University of Pennsylvania
Check if you qualify for this giant cell arteritis clinical trial in New York, NY
If you're searching for giant cell arteritis treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced giant cell arteritis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.